The Serious Fraud Office has closed its investigation of GlaxoSmithKline PLC and declined to prosecute entities or individuals connected with the company. The investigation, first announced by the SFO in May 2014, focused on commercial practices by the company and its subsidiaries. In September 2016, GSK settled related charges by the Securities and Exchange Commission that the company, through its Chinese subsidiary, violated the books and records and internal controls provisions of the FCPA, agreeing to pay a civil penalty of $20 million, to improve its anti-corruption policies and procedures, and to submit to a two-year period of self-monitoring and reporting.
February 22, 2019
SFO closes investigation of UK pharmaceutical company
Related by Topic
New Post
DOJ settles FCPA investigation with reinsurance brokers Tysers and H.W. Wood
November 24, 2023
News Alert
DOJ issues FCPA Opinion Procedure Release concerning stipends for foreign officials
November 12, 2023
News Alert